Corrigendum to “Microglial NLRP3 inflammasome activation mediates IL-1beta-related inflammation in prefrontal cortex of depressive rats” [Brain Behav. Immun. 41 (2014) 90–100](S0889159114001202)(10.1016/j.bbi.2014.04.007);Microglial NLRP3 inflammasome activation mediates IL-1β-related inflammation in prefrontal cortex of depressive rats

Brain, Behavior, and Immunity

Volumn 41, Issue 1, 2014, Pages 90-100

  Pan, Ying ^a   Chen, Xu Yang ^a   Zhang, Qing Yu ^a   Kong, Ling Dong ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Chronic unpredictable mild stress; Depression; IL 1 related CNS inflammation; NLRP3 inflammasome; Prefrontal cortex

Indexed keywords

CRYOPYRIN; FLUOXETINE; GLUTAMATE AMMONIA LIGASE; GLUTAMIC ACID; GLUTAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NEURON SPECIFIC NUCLEAR PROTEIN; TOLL LIKE RECEPTOR 2; ACTIN BINDING PROTEIN; AIF1 PROTEIN, RAT; ANTIDEPRESSANT AGENT; CALCIUM BINDING PROTEIN; CELL RECEPTOR; IL1B PROTEIN, RAT; INFLAMMASOME; NERVE PROTEIN; NOD-LIKE RECEPTOR 3, RAT; SUCROSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; MALE; MICROGLIA; NONHUMAN; OLIGOMERIZATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; SUCROSE PREFERENCE TEST; ANHEDONIA; ANIMAL; BIOSYNTHESIS; BLOOD; CEREBROSPINAL FLUID; CHRONIC DISEASE; DEPRESSIVE DISORDER; DRINKING BEHAVIOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; PATHOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY; RANDOMIZATION; WISTAR RAT;

ANHEDONIA; ANIMALS; ANTIDEPRESSIVE AGENTS; CALCIUM-BINDING PROTEINS; CHRONIC DISEASE; DEPRESSIVE DISORDER; DRINKING BEHAVIOR; ENZYME ACTIVATION; FLUOXETINE; GENE EXPRESSION REGULATION; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; MALE; MICROFILAMENT PROTEINS; MICROGLIA; NERVE TISSUE PROTEINS; NF-KAPPA B; PREFRONTAL CORTEX; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRESS, PHYSIOLOGICAL; SUCROSE;

EID: 84924052001     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2021.08.221     Document Type: Erratum

References (75)

1. Alboni S., Benatti C., Montanari C., Tascedda F., Brunello N. Chronic antidepressant treatments resulted in altered expression of genes involved in inflammation in the rat hypothalamus. Eur. J. Pharmacol. 2013, 721:158-167.
2. Alcocer-Gomez E., de Miguel M., Casas-Barquero N., Nunez-Vasco J., Sanchez-Alcazar J.A., Fernandez-Rodriguez A., Cordero M.D. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav. Immun. 2014, 36:111-117.
3. Babelova A., Moreth K., Tsalastra-Greul W., Zeng-Brouwers J., Eickelberg O., Young M.F., Bruckner P., Pfeilschifter J., Schaefer R.M., Grone H.J., Schaefer L. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem. 2009, 284:24035-24048.
4. Banasr M., Duman R.S. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol. Psychiatry 2008, 64:863-870.
5. Banasr M., Chowdhury G.M., Terwilliger R., Newton S.S., Duman R.S., Behar K.L., Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol. Psychiatry 2010, 15:501-511.
6. Barden N. Glucocorticoids and P2RX7: a susceptibility gene for depressive disorders. FENS Abstr. 2006, 3(A032):4.
7. Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., Fernandes-Alnemri T., Wu J., Monks B.G., Fitzgerald K.A., Hornung V., Latz E. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 2009, 183:787-791.
8. Beasley C.M., Nilsson M.E., Koke S.C., Gonzales J.S. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. J. Clin. Psychiatry 2000, 61:722-728.
9. Bianchi M., Sacerdote P., Panerai A.E. Fluoxetine reduces inflammatory edema in the rat: involvement of the pituitary-adrenal axis. Eur. J. Pharmacol. 1994, 263:81-84.
10. Brambilla F., Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr. Scand. 1998, 97:309-313.
11. Busillo J.M., Azzam K.M., Cidlowski J.A. Glucocorticoids sensitize the innate immune system through regulation of the NLRP3 inflammasome. J. Biol. Chem. 2011, 286:38703-38713.
12. Chung Y.C., Kim S.R., Park J.Y., Chung E.S., Park K.W., Won S.Y., Bok E., Jin M., Park E.S., Yoon S.H., Ko H.W., Kim Y.S., Jin B.K. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011, 60:963-974.
13. Couch Y., Anthony D.C., Dolgov O., Revischin A., Festoff B., Santos A.I., Steinbusch H.W., Strekalova T. Microglial activation, increased TNF and SERT expression in the prefrontal cortex define stress-altered behaviour in mice susceptible to anhedonia. Brain Behav. Immun. 2013, 29:136-146.
14. d'Audiffret A.C., Frisbee S.J., Stapleton P.A., Goodwill A.G., Isingrini E., Frisbee J.C. Depressive behavior and vascular dysfunction: a link between clinical depression and vascular disease?. J. Appl. Physiol. 2010, 108:1041-1051.
15. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 2005, 6:463-475.
16. de Rivero Vaccari J.P., Lotocki G., Marcillo A.E., Dietrich W.D., Keane R.W. A molecular platform in neurons regulates inflammation after spinal cord injury. J. Neurosci. 2008, 28:3404-3414.
17. Dhami K.S., Churchward M.A., Baker G.B., Todd K.G. Fluoxetine and citalopram decrease microglial release of glutamate and D-serine to promote cortical neuronal viability following ischemic insult. Mol. Cell Neurosci. 2013, 56:365-374.
18. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
19. Elizalde N., Garcia-Garcia A.L., Totterdell S., Gendive N., Venzala E., Ramirez M.J., Del Rio J., Tordera R.M. Sustained stress-induced changes in mice as a model for chronic depression. Psychopharmacology 2010, 210:393-406.
20. Fann D.Y., Lee S.Y., Manzanero S., Tang S.C., Gelderblom M., Chunduri P., Bernreuther C., Glatzel M., Cheng Y.L., Thundyil J., Widiapradja A., Lok K.Z., Foo S.L., Wang Y.C., Li Y.I., Drummond G.R., Basta M., Magnus T., Jo D.G., Mattson M.P., Sobey C.G., Arumugam T.V. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis. 2013, 4:e790.
21. Farooq R.K., Isingrini E., Tanti A., Le Guisquet A.M., Arlicot N., Minier F., Leman S., Chalon S., Belzung C., Camus V. Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation?. Behav. Brain Res. 2012, 231:130-137.
22. Frank M.G., Watkins L.R., Maier S.F. Stress- and glucocorticoid-induced priming of neuroinflammatory responses: potential mechanisms of stress-induced vulnerability to drugs of abuse. Brain Behav. Immun. 2011, 25(Suppl. 1):S21-S28.
23. Frank M.G., Thompson B.M., Watkins L.R., Maier S.F. Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses. Brain Behav. Immun. 2012, 26:337-345.
24. Gadek-Michalska A., Tadeusz J., Rachwalska P., Bugajski J. Cytokines, prostaglandins and nitric oxide in the regulation of stress-response systems. Pharmacol. Rep. 2013, 65:1655-1662.
25. Garcia-Garcia A.L., Elizalde N., Matrov D., Harro J., Wojcik S.M., Venzala E., Ramirez M.J., Del Rio J., Tordera R.M. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol. Psychiatry 2009, 66:275-282.
26. Grippo A.J., Francis J., Beltz T.G., Felder R.B., Johnson A.K. Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia. Physiol. Behav. 2005, 84:697-706.
27. Grippo A.J., Beltz T.G., Weiss R.M., Johnson A.K. The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biol. Psychiatry 2006, 59:309-316.
28. Guillemin G.J., Brew B.J. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J. Leukoc. Biol. 2004, 75:388-397.
29. Guillemin G., Boussin F.D., Croitoru J., Franck-Duchenne M., Le Grand R., Lazarini F., Dormont D. Obtention and characterization of primary astrocyte and microglial cultures from adult monkey brains. J. Neurosci. Res. 1997, 49:576-591.
30. Haneklaus M., O'Neill L.A., Coll R.C. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr. Opin. Immunol. 2013, 25:40-45.
31. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
32. Heneka M.T., Kummer M.P., Stutz A., Delekate A., Schwartz S., Vieira-Saecker A., Griep A., Axt D., Remus A., Tzeng T.C., Gelpi E., Halle A., Korte M., Latz E., Golenbock D.T. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493:674-678.
33. Iwata M., Ota K.T., Duman R.S. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav. Immun. 2013, 31:105-114.
34. Jha S., Srivastava S.Y., Brickey W.J., Iocca H., Toews A., Morrison J.P., Chen V.S., Gris D., Matsushima G.K., Ting J.P. The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J. Neurosci. 2010, 30:15811-15820.
35. Jin Y., Lim C.M., Kim S.W., Park J.Y., Seo J.S., Han P.L., Yoon S.H., Lee J.K. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res. 2009, 1281:108-116.
36. Kagaya A., Kugaya A., Takebayashi M., Fukue-Saeki M., Saeki T., Yamawaki S., Uchitomi Y. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 2001, 43:59-62.
37. Koh S.J., Kim J.M., Kim I.K., Kim N., Jung H.C., Song I.S., Kim J.S. Fluoxetine inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G9-G19.
38. Koo J.W., Duman R.S. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:751-756.
39. Kupfer D.J., Frank E., Phillips M.L. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012, 379:1045-1055.
40. Levine J., Barak Y., Chengappa K.N., Rapoport A., Rebey M., Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999, 40:171-176.
41. Liu D., Wang Z., Liu S., Wang F., Zhao S., Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology 2011, 61:592-599.
42. Liu H.D., Li W., Chen Z.R., Hu Y.C., Zhang D.D., Shen W., Zhou M.L., Zhu L., Hang C.H. Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model. Neurochem. Res. 2013, 38:2072-2083.
43. Lucae S., Salyakina D., Barden N., Harvey M., Gagne B., Labbe M., Binder E.B., Uhr M., Paez-Pereda M., Sillaber I., Ising M., Bruckl T., Lieb R., Holsboer F., Muller-Myhsok B. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum. Mol. Genet. 2006, 15:2438-2445.
44. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:664-675.
45. Martinez J.M., Garakani A., Yehuda R., Gorman J.M. Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. Depress. Anxiety 2012, 29:32-38.
46. Maslanik T., Mahaffey L., Tannura K., Beninson L., Greenwood B.N., Fleshner M. The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stressor exposure. Brain Behav. Immun. 2013, 28:54-62.
47. Mason J.L., Suzuki K., Chaplin D.D., Matsushima G.K. Interleukin-1beta promotes repair of the CNS. J. Neurosci. 2001, 21:7046-7052.
48. McBean G.J. Inhibition of the glutamate transporter and glial enzymes in rat striatum by the gliotoxin, alpha aminoadipate. Br. J. Pharmacol. 1994, 113:536-540.
49. McKlveen J.M., Myers B., Flak J.N., Bundzikova J., Solomon M.B., Seroogy K.B., Herman J.P. Role of prefrontal cortex glucocorticoid receptors in stress and emotion. Biol. Psychiatry 2013, 74:672-679.
50. Miguel-Hidalgo J.J., Baucom C., Dilley G., Overholser J.C., Meltzer H.Y., Stockmeier C.A., Rajkowska G. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol. Psychiatry 2000, 48:861-873.
51. Mormede C., Castanon N., Medina C., Moze E., Lestage J., Neveu P.J., Dantzer R. Chronic mild stress in mice decreases peripheral cytokine and increases central cytokine expression independently of IL-10 regulation of the cytokine network. Ann. NY Acad. Sci. 2002, 10:359-366.
52. Nadjar A., Bluthe R.M., May M.J., Dantzer R., Parnet P. Inactivation of the cerebral NFkappaB pathway inhibits interleukin-1beta-induced sickness behavior and c-Fos expression in various brain nuclei. Neuropsychopharmacology 2005, 30:1492-1499.
53. Norman G.J., Karelina K., Zhang N., Walton J.C., Morris J.S., Devries A.C. Stress and IL-1beta contribute to the development of depressive-like behavior following peripheral nerve injury. Mol. Psychiatry 2010, 15:404-414.
54. Owen B.M., Eccleston D., Ferrier I.N., Young A.H. Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr. Scand. 2001, 103:226-228.
55. Pan Y., Zhang W.Y., Xia X., Kong L.D. Effects of icariin on hypothalamic-pituitary-adrenal axis action and cytokine levels in stressed Sprague-Dawley rats. Biol. Pharm. Bull. 2006, 29:2399-2403.
56. Pan Y., Kong L.D., Li Y.C., Xia X., Kung H.F., Jiang F.X. Icariin from Epimedium brevicornum attenuates chronic mild stress-induced behavioral and neuroendocrinological alterations in male Wistar rats. Pharmacol. Biochem. Behav. 2007, 87:130-140.
57. Pan Y., Wang F.M., Qiang L.Q., Zhang D.M., Kong L.D. Icariin attenuates chronic mild stress-induced dysregulation of the LHPA stress circuit in rats. Psychoneuroendocrinology 2010, 35:272-283.
58. Pan Y., Hong Y., Zhang Q.Y., Kong L.D. Impaired hypothalamic insulin signaling in CUMS rats: restored by icariin and fluoxetine through inhibiting CRF system. Psychoneuroendocrinology 2013, 38:122-134.
59. Pandey G.N., Rizavi H.S., Ren X., Fareed J., Hoppensteadt D.A., Roberts R.C., Conley R.R., Dwivedi Y. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J. Psychiatr. Res. 2012, 46:57-63.
60. Papp M., Willner P., Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology 1991, 104:255-259.
61. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008, 31:464-468.
62. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS Neurol. Disord. Drug Targets 2007, 6:219-233.
63. Ransohoff R.M., Brown M.A. Innate immunity in the central nervous system. J Clin. Invest. 2012, 122:1164-1171.
64. Sanacora G., Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol. Psychiatry 2013, 73:1172-1179.
65. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., Mirnics K. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 2011, 16:751-762.
66. Silverman W.R., de Rivero Vaccari J.P., Locovei S., Qiu F., Carlsson S.K., Scemes E., Keane R.W., Dahl G. The pannexin 1 channel activates the inflammasome in neurons and astrocytes. J. Biol. Chem. 2009, 284:18143-18151.
67. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., Bernstein H.G., Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 2008, 42:151-157.
68. Sugama S., Fujita M., Hashimoto M., Conti B. Stress induced morphological microglial activation in the rodent brain: involvement of interleukin-18. Neuroscience 2007, 146:1388-1399.
69. Takuma K., Baba A., Matsuda T. Astrocyte apoptosis: implications for neuroprotection. Prog. Neurobiol. 2004, 72:111-127.
70. Weber M.D., Frank M.G., Sobesky J.L., Watkins L.R., Maier S.F. Blocking toll-like receptor 2 and 4 signaling during a stressor prevents stress-induced priming of neuroinflammatory responses to a subsequent immune challenge. Brain Behav. Immun. 2013, 32:112-121.
71. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 1997, 134:319-329.
72. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987, 93:358-364.
73. You Z., Luo C., Zhang W., Chen Y., He J., Zhao Q., Zuo R., Wu Y. Pro- and anti-inflammatory cytokines expression in rat's brain and spleen exposed to chronic mild stress: involvement in depression. Behav. Brain Res. 2011, 225:135-141.
74. Zou J., Crews F.T. Inflammasome-IL-1beta signaling mediates ethanol inhibition of hippocampal neurogenesis. Front. Neurosci. 2012, 6:77.
75. Zou J., Vetreno R.P., Crews F.T. ATP-P2X7 receptor signaling controls basal and TNFalpha-stimulated glial cell proliferation. Glia 2012, 60:661-673.